Fuse E - Search Results

1

Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities.

Kajita J, Inano K, Fuse E, Kuwabara T, Kobayashi H. Kajita J, et al. Among authors: fuse e. Drug Metab Dispos. 2002 Dec;30(12):1504-11. doi: 10.1124/dmd.30.12.1504. Drug Metab Dispos. 2002. PMID: 12433826

2

The contribution of cytochrome P450 to the metabolism of tegafur in human liver.

Kajita J, Fuse E, Kuwabara T, Kobayashi H. Kajita J, et al. Among authors: fuse e. Drug Metab Pharmacokinet. 2003;18(5):303-9. doi: 10.2133/dmpk.18.303. Drug Metab Pharmacokinet. 2003. PMID: 15618749 Free article.

3

Effect of benidipine on simvastatin metabolism in human liver microsomes.

Sugiyama Y, Mimura N, Kuwabara T, Kobayashi H, Ushiki J, Fuse E. Sugiyama Y, et al. Among authors: fuse e. Drug Metab Pharmacokinet. 2007 Jun;22(3):199-205. doi: 10.2133/dmpk.22.199. Drug Metab Pharmacokinet. 2007. PMID: 17603221 Free article.

4

P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist.

Mimura N, Nagata Y, Kuwabara T, Kubo N, Fuse E. Mimura N, et al. Among authors: fuse e. Drug Metab Pharmacokinet. 2008;23(2):106-14. doi: 10.2133/dmpk.23.106. Drug Metab Pharmacokinet. 2008. PMID: 18445990 Free article.

5

Monoamine oxidase B oxidizes a novel multikinase inhibitor KW-2449 to its iminium ion and aldehyde oxidase further converts it to the oxo-piperazine form in human.

Hosogi J, Ohashi R, Maeda H, Tashiro S, Fuse E, Yamamoto Y, Kuwabara T. Hosogi J, et al. Among authors: fuse e. Drug Metab Pharmacokinet. 2017 Oct;32(5):255-264. doi: 10.1016/j.dmpk.2017.06.002. Epub 2017 Jun 22. Drug Metab Pharmacokinet. 2017. PMID: 28751116

6

Pharmacokinetics, distribution, metabolism and excretion of.

Yasoshima K, Kuwabara T, Fuse E, Kuramitu T, Kurata N, Nishiie H, Oishi T, Kobayashi H, Kobayashi S. Yasoshima K, et al. Among authors: fuse e. Cancer Chemother Pharmacol. 2001;47(2):106-12. doi: 10.1007/s002800000213. Cancer Chemother Pharmacol. 2001. PMID: 11269735

7

Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs.

Fuse E, Nishiie H, Kobayashi H, Ikeda S, Saito H, Covey J, Kobayashi S. Fuse E, et al. Eur J Drug Metab Pharmacokinet. 1997 Jan-Mar;22(1):53-63. doi: 10.1007/BF03189785. Eur J Drug Metab Pharmacokinet. 1997. PMID: 9179561

8

Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.

Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, Kuwabara T, Kobayashi S, Sugiyama Y. Fuse E, et al. Cancer Res. 1999 Mar 1;59(5):1054-60. Cancer Res. 1999. PMID: 10070963

9

Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors.

Ishida H, Isami S, Matsumura T, Umehara H, Yamashita Y, Kajita J, Fuse E, Kiyoi H, Naoe T, Akinaga S, Shiotsu Y, Arai H. Ishida H, et al. Among authors: fuse e. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5472-7. doi: 10.1016/j.bmcl.2008.09.031. Epub 2008 Sep 11. Bioorg Med Chem Lett. 2008. PMID: 18835166

10

[Study of disposition of adriamycin and mitomycin C in liver by determination of plasma concentrations in hepatic vein and artery during intravenous constant infusion in rats].

Fuse E, Takai K, Kobayashi H, Kobayashi S. Fuse E, et al. Gan To Kagaku Ryoho. 1997 Jun;24(8):975-9. Gan To Kagaku Ryoho. 1997. PMID: 9212807 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters